SLC5A2 and heart failure: The EMPA-REG OUTCOME trial, including over 7000 diabetic patients with cardiovascular diseases, showed that empagliflozin, a SGLT-2 inhibitor, reduced risk of death from cardiovascular causes, and decreased risk of hospitalization for heart failure [2].